Breaking Research News from sources other than Breastcancer.org
Comments
-
Symptom Cluster of Emotional Distress, Fatigue, and Cognitive Difficulties Among Young and Older Breast Cancer Survivors
https://www.practiceupdate.com/c/71986/67/13/?elsc...
Original source: Journal of Geriatric Oncology
- This study enrolled 170 breast cancer survivors 1 to 12 months post chemotherapy with stage I–III disease to examine the nature of the symptom cluster of emotional distress, fatigue, and cognitive problems. The authors also assessed the mediating role of subjective stress and coping strategies (emotional control and meaning-focused coping) in the association between age and symptom cluster.
- The authors found that lower levels of subjective stress, but not coping strategies, mediated the association of age with the symptom cluster of emotional distress, fatigue, and cognitive difficulty and concluded that further research is needed to explore differences in subjective stress by age.
0 -
Thanks Lumpie, I've never heard of Talazoparib, so will be watching this.
(Not sure why this duplicated three times ? ?)
0 -
Thanks Lumpie, I've never heard of Talazoparib, so will be watching this.
0 -
Thanks Lumpie, I've never heard of Talazoparib, so will be watching this.
0 -
0
-
Saving money on Breast Cancer Screening..
Breast Cancer Screening Only for Women at Higher Risk
Nick Mulcahy
July 05, 2018
https://www.medscape.com/viewarticle/8989240 -
Another way to save on us, let the PCP follow-up.
Breast Cancer Survivors: Transition to PCP Leads to Savings
Roxanne Nelson, RN, BSN
February 22, 2018
https://www.medscape.com/viewarticle/8929890 -
Apelisib - New targeted drug for hormone positive, Her 2 negative breast cancer
0 -
Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale Sequencing
Published in: JAMA Oncology
https://www.practiceupdate.com/C/72231/56?elsca1=e...
- In this study assessing whole-exome sequencing results from 11,416 patients with breast cancer, ovarian cancer, or both and 3988 controls, an increased risk of breast cancer was associated with PALB2, ATM, CHEK2, and MSH6 genes, whereas MSH6, RAD51C, TP53, and ATM genes were associated with an increased risk of ovarian cancer.
- In addition to confirming several well-known breast or ovarian cancer gene associations, this study identified MSH6 and ATM as possible moderate-risk breast and ovarian cancer predisposition genes, respectively.
0 -
Meaningful Activity of Poziotinib in HER2+ MBC After ≥2 Prior HER2-Directed Regimens
Published in: International Journal of Cancer
https://www.practiceupdate.com/c/71250/67/13/?elsc...
- In this open-label, multicenter phase II study, 106 patients with HER2-positive metastatic breast cancer were treated with 12 mg poziotinib once daily on a 14-day on/7-day off schedule. After a median follow-up of 12 months, the median progression-free and overall survival were 4.04 months and not reached, respectively. Frequently reported treatment-related adverse events were diarrhea, stomatitis, and rashes.
- These findings highlight the need for biomarker studies to support further investigation of poziotinib.
0 -
Hypnosis Doesn't Cut Post-Op Pain in Breast Cancer Surgery
Those who perceived that they received hypnosis had significantly reduced fatigue and anxiety
Published in: HealthDay
https://www.practiceupdate.com/C/72402/56?elsca1=e...
0 -
Cure Magazine - best article on Thyroid Nodules
https://www.curetoday.com/publications/cure/2018/s...0 -
Prmary breast cancer can 'shut down its own spread'
Published TodayBy Ana Sandoiu
Fact checked by Jasmin Collier
https://www.medicalnewstoday.com/articles/322898.p...0 -
marijen, I wish I could give your "oh, really?" post a thumbs up! Love the pic and that title sounds tauntingly optimistic.
The idea of the immune system stopping cancer is certainly encouraging, but I think that we already knew that the immune system is often able to stops cancer - or we would see advanced cases much more often. According to the article "By some estimates, less than 0.02 percent of breakaway cells will form secondary tumors." So, 'bless their hearts,' our hard-working immune systems are already 99.98% effective. The article suggests that certain types of immune responses may be more effective and that perhaps that type of response could be encouraged or enhanced. This may represent a therapeutic opportunity. I certainly hope so!
0 -
-
Thanks for the excellent link to the MSKCC research, Chemokaze. Fascinating! Here are highlights for those who need a synopsis:
In a Twist, Scientists Find Cancer Drivers Hiding in RNA, Not DNA
Researchers at the Sloan Kettering Institute have found that changes in an information-carrying molecule called messenger RNA can inactivate tumor-suppressing proteins and thereby promote cancer. The findings pinpoint previously unknown drivers of the disease.
...between DNA and proteins is another layer of information, called messenger RNA (mRNA), which serves as a crucial link between the two. New research suggests that mRNA itself may carry cancer-causing changes. And, because genetic tests don't usually look at mRNA, those changes have so far gone undetected by cancer doctors. "But these mRNA changes have the same ultimate effect as known cancer drivers in DNA, so we believe they may play a very important role."
Christine Mayr, a molecular biologist at the Sloan Kettering Institute is the senior author of a new paper on the topic published today in Nature. (Monday, August 27, 2018)
https://www.mskcc.org/blog/scientists-find-cancer-...
0 -
Lumpie:
Not just the coffee. They have put these warnings up in the bread and canned black olive section of the supermarket as well.
0 -
Survival of De Novo Stage IV HER2+ Breast Cancers Treated With HER2-Targeted Therapy
https://www.practiceupdate.com/c/72529/67/13/?elsc...
Published in The Oncologist
http://theoncologist.alphamedpress.org/content/ear...
- This retrospective study of 483 patients at two institutions (Yale and MD Anderson Cancer Centers) reports outcomes among patients with de novo stage IV HER2-positive breast cancer treated with HER2-directed therapy. Median OS was 5.5 years. Among the 13% of patients who achieved no evidence of disease (NED) status, PFS and OS rates at 5 years were 100% and 98%, respectively. Patients often required resection of solitary metastases to achieve NED status.
- Notably, results were maintained at 10 years.
- NED patients more frequently had solitary metastasis and surgery to resect cancer.
- NED status and estrogen receptor positive status were associated with prolonged OS.
{This is very reassuring news for relevant populations!}0 -
Thanks Lumpie, great read. Also, I was delighted to see that the Oncologist article was written (in part) by my MO (Murthy) 😀
0 -
Not breaking news, Aug.2017
Alternative Medicine Kills Cancer Patients, Study Finds
0 -
Circulating MicroRNAs in Breast Cancer as an Indicator of Clinical Response to Neoadjuvant Chemotherapy
https://www.practiceupdate.com/C/72254/56?elsca1=e...
Published in Cancer Medicine
- This study looked at the association of plasma circulating microRNA with response to neoadjuvant chemotherapy in 109 patients with operable or locally advanced breast cancer.
- Several early markers were identified for predicting response to neoadjuvant chemotherapy in HR+/HER2− disease.
- ...dynamics of circulating miRNAs might help predict clinical response to neoadjuvant chemotherapy in breast cancer.
0 -
Maryjean...are you aware that 99% of stage four cancer patients will NOT survive the five years mark?
And that 30% of stage one and two patients that undergo the recommended treatment and take hormonal medications for the next 10 years will be diagnosed stage four regardless??
Are you aware that during the latest ASCO meeting it was decided that stage one and two should not undergo the typical protocols.
More interesting still, do you know that all the medications we have to take are unreliable and unpredictable for the same type of cancers as classified by their own scientific methods? At our best institutions?
Isn't the definition of scientific an observable repeatable event? Well there's nothings scientific or predictable with cancer medications.. what's predictable is that they wreak what's still working in our bodies and that most of them are ancerogenic. Look up tamoxifen warning sheet, it's at the top of a five pages list of health problems.
I'm not defending the alternative cures here, as they too seem to miss the mark by a mile. But why call them quacks when the other side have the highest rate of failure while being paid exhurbitant amount of money and receiving all the grants and reasearch money?
Just because we don't have viable choices doesn't make what we do have less ridiculous.
let's hope that both sides can start thinking outside the box and can provide real answers and solutions to a diseases that affects and will likely kill 1in 2 Americans over their lifetime.
0 -
I’m sorry if I upset you Miaomix, it’s only a study and I think it is about ONLY doing alternative treatment. There isn’t much rhyme or reason to the treatments we are given. Yes I do know 30% go on to stage IV and Stage IV does not have a good survival rate. I did not have chemo and am an antihormonal dropout. Thank you for your informative post.
If we knew what it was we were doing, it would not be called research, would it? —Albert Einstein
0 -
Can you explain what happened at ASCO regarding Stage 1 and 2
0 -
I think the stats speak clearly for themselves. If you have scientific treatment, your odds of living longer are improved over Alternative treatment alone. So if 30% get terminal cancer at 10 years on standard treatment, 50% would on alternative alone treatment. Math is math. Marijen was correct in posting the link.
0 -
Thank you Lisey. Miaomix I also would like the link on the ASCO Conference.
Somatic mutations in early onset luminal breast cancer
Giselly Encinas, Veronica Y. Sabelnykova, [...], and Maria Aparecida Azevedo Koike Folgueira
0 -
I guess i will be the one to correct Miaomix on her stage 4 99% 5 year statement. Below is from July 2017- more than1 in 5 will be alive after 5 years. Heartbreaking but not 1%.
The American Cancer Society (ACS) states that the five-year survival rate after diagnosis for people with stage 4 breast cancer is 22 percent.
That's all. Thanks
0 -
Better news anyways Brigid TO, Thanks.
Where Does Breast Cancer Spread?
Readabout the symptoms to watch for: https://www.verywellhealth.com/where-does-breast-c...
Excerpt
The most common first site of metastases was looked at in a 2013 study. Women with early stage breast cancer were evaluated to see what location was the most common first site of metastasis with their cancer. The breakdown was:
- Bones - 41 percent
- Lungs - 22 percent
- Liver - 7.3 percent
- Brain - 7.3 percent
- Other sites were the first location of metastasis in the remaining people
0 -
Ten Practice Changes That I Will Make After Attending ASCO 2018
https://www.practiceupdate.com/content/ten-practic...
"Editorial" from an MO. Only a few of these are re breast cancer - but it may be of interest to some.
0 -
There was some discussion above about 5 year survival rates. I thought I would post some statistical sources. The American Cancer Society say "Metastatic, or stage IV breast cancers, have a 5-year relative survival rate of about 22%." (cancer.org link below)
A fairly recent page on cancer.gov says "...researchers estimated that between 1992-1994 and 2005-2012, five-year relative survival among women initially diagnosed with MBC at ages 15-49 years doubled from 18 percent to 36 percent.... More than 11 percent of women diagnosed between 2000-2004 under the age of 64 survived 10 years or more.... one-third (34 percent) of women with MBC have lived for five years or more with the disease." (cancer.gov link below)
If we had better SEER data, we would know more about how we are really doing. Keep lobbying! Don't ignore Stage IV! There is a great discussion of why we don't have good numbers on how many people are living with stage IV here: https://www.change.org/p/seer-start-counting-all-p... (You can also sign the petition if you choose.)
https://www.cancer.org/cancer/breast-cancer/unders...
https://www.cancer.gov/news-events/press-releases/...
0
